Targeting macrophages to treat pancreatic cancer
Mené sur 47 patients atteints d'un adénocarcinome canalaire du pancréas de stade localement avancé et résécable, cet essai de phase Ib évalue la toxicité et l'activité antitumorale d'un inhibiteur de CCR2 en complément d'une chimiothérapie FOLFIRINOX
In the past two decades, little progress has been made in the systemic treatment of pancreatic cancer. The only successes were with traditional cytotoxic drugs that resulted in very small increments in survival. The failure of molecularly-based therapies to deliver a clinically meaningful benefit was based on targeting of single molecules or pathways, such as EGFR, insulin-like growth-factor-1 receptor, VEGF, VEGF receptor, and MEK,2,3 With improved understanding of biology, other targets worthy of clinical testing were identified, especially those related to the stroma and cancer stem cells.
The Lancet Oncology , commentaire, 2015